Reported Saturday, Immatics Presents Expanded IMA203 PRAME Cell Therapy Results At ASCO: Durable Objective Responses In 91% Of Patients And Favorable Safety Profile

Author: Benzinga Newsdesk | June 02, 2025 03:52am

• Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years
   
• IMA203 PRAME cell therapy one-time infusion in all melanoma patients shows cORR of 56%; mDOR of 12.1 months at mFU of 13.4 months; mPFS of 6.1 months; mOS of 15.9 months
  
  
  • Cutaneous melanoma subgroup post-checkpoint inhibitor shows cORR of 50%, mDOR not reached at mFU of 16.7 months; mPFS of 6.0 months
  • Uveal melanoma subgroup, including tebentafusp-refractory patients shows cORR of 67%, mDOR of 11.0 months at mFU of 13.4 months; mPFS of 8.5 months
     
• Positive Phase 1b data and high PRAME prevalence in melanoma reinforce the basis for the ongoing SUPRAME Phase 3 trial in previously treated advanced or metastatic cutaneous melanoma, as well as the continued Phase 1b expansion in uveal melanoma
   
• ASCO presentations further substantiate Immatics' global leadership in precision targeting of PRAME and potential of IMA203 to be the Company's first PRAME product
   

Posted In: IMTX